Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Platinum compounds

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Platinum compounds. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-015770-35 Sponsor Protocol Number: 1230.18 Start Date*: 2010-03-17
    Sponsor Name:Boehringer Ingelheim France
    Full Title: Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cyto...
    Medical condition: Recurrent ovarian cancer resistant or refractory to platinum compounds
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) SE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-002018-23 Sponsor Protocol Number: ONC-2008-001 Start Date*: 2008-10-21
    Sponsor Name:FONDAZIONE HUMANITAS PER LA RICERCA
    Full Title: MULTICENTRIC RANDOMIZED PHASE III STUDY COMPARING GEFITINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN EGFR FISH POSITIVE NSCLC PATIENTS (RANGE)
    Medical condition: Patients with locally advanced or metastatic NSCLC, EGFR FISH positive, candidate for a first-line platinum-based chemotherapy will be considered eligible for the trial.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025065 Lung carcinoma cell type unspecified recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002513-36 Sponsor Protocol Number: ASP-1929-301 Start Date*: 2019-08-16
    Sponsor Name:Rakuten Aspyrian, Inc.
    Full Title: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck ...
    Medical condition: Locoregional, recurrent head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GR (Completed) BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002914-10 Sponsor Protocol Number: 66856 Start Date*: 2019-09-16
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial
    Medical condition: Advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004499-38 Sponsor Protocol Number: CCR 3116 Start Date*: 2010-04-16
    Sponsor Name:Royal Marsden NHS Foundation Trust
    Full Title: A randomised double-blind placebo-controlled trial of the safety and efficacy of ethosuximide 250mg capsules for the management of chemotherapy-induced painful peripheral neuropathy.
    Medical condition: The medicial condition under investigation is chemotherapy-induced painful peripheral neuropathy (CIPPN). CIPPN is a complication of several classes of chemotherapy agents e.g taxanes (paclitaxel, ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036109 Polyneuropathy due to drugs LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001005-82 Sponsor Protocol Number: TALL/IP/2 Start Date*: 2015-05-05
    Sponsor Name:Galileo Research Srl
    Full Title: Phase II trial of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with ovarian carcinoma with minimal or microscopic residual disease at second look laparotom...
    Medical condition: Ovarian carcinoma (FIGO stage IIIA and IIIB/IIIC/IV; patients with extra-abdominal disease will be excluded by the study unless those with pleural effusion) with minimal/microscopic residual disease.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011041-12 Sponsor Protocol Number: ET-A-018-09 Start Date*: 2009-07-23
    Sponsor Name:Pharma Mar S.A.
    Full Title: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.
    Medical condition: Pretreated Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002002-70 Sponsor Protocol Number: BIT-2 Start Date*: 2011-07-30
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: A RANDOMISED PHASE II TRIAL OF SECOND LINE THERAPY IN ADVANCED BILIARY TRACT CANCER: CAPECITABINE OR CAPECITABINE PLUS MITOMYCIN C (BIT-2)
    Medical condition: Locally advanced or metastatic adenocarcinoma of the biliary tract (intra or extra-hepatic biliary ducts, gallbladder, Ampulla of Vater).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025734 Malignant neoplasm of biliary tract, part unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002860-25 Sponsor Protocol Number: ML19944 Start Date*: 2006-09-27
    Sponsor Name:Roche Hungary Ltd.
    Full Title: A multicenter randomized phase II trial to compare trastuzumab (Herceptin®) continuation or discontinuation in combination with 2nd-line chemotherapies after progression on a 1st-line chemotherapy ...
    Medical condition: Metastacic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) EE (Completed) LT (Completed) SK (Completed) LV (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-001319-36 Sponsor Protocol Number: FIERCE-21(B-701-U21) Start Date*: 2017-08-23
    Sponsor Name:BioClin Therapeutics, Inc.
    Full Title: A Dose Escalation, Expansion Study of Vofatamab (B 701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After,...
    Medical condition: Treatment of progressed or refractory metastatic UCC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004429-41 Sponsor Protocol Number: BAY43-9006/12007 Start Date*: 2008-10-03
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a ...
    Medical condition: The study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033164 Ovarian epithelial cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033163 Ovarian epithelial cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) FI (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002472-34 Sponsor Protocol Number: EGF109462 Start Date*: 2007-08-06
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer
    Medical condition: Patients with advanced or metatstatic Non-Small Cell Lung Cancer who have received one prior platinum containing chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000703-42 Sponsor Protocol Number: ML 18742 Start Date*: 2006-05-17
    Sponsor Name:ROCHE
    Full Title: A phase III randomized trial of trastuzumab continuation vs discontinuation in combination with 2nd-line chemotherapy after progression on a 1st-line trastuzumab-chemotherapy combination for HER2 ...
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005621-24 Sponsor Protocol Number: N14PLU Start Date*: 2014-07-17
    Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
    Full Title: PeRsOnalized treatment fOr patients with pleural eFfusions due to malignant pleural mesothelioma or lung cancer in second or third line. An open label phase II study (Acronym: the PROOF study)
    Medical condition: Proven pleural effusion of malignant pleural mesothelioma or non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10066490 Progression of non-small cell lung cancer LLT
    17.0 100000004864 10027408 Mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002525-19 Sponsor Protocol Number: D5660C00004 Start Date*: 2016-01-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients ...
    Medical condition: Part A (US ONLY): advanced solid malignancies Part B (NA, EU): Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    26.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Restarted) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000324-29 Sponsor Protocol Number: CA011-001 Start Date*: 2016-09-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors
    Medical condition: Serious ovarian cancer with wild-type BRCA1/2, triple negative breast cancer and small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001501-24 Sponsor Protocol Number: AVETRIC Start Date*: 2020-02-13
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: PHASE II STUDY OF AVELUMAB AND CETUXIMAB AND MODIFIED FOLFOXIRI AS INITIAL THERAPY FOR RAS WILD-TYPE UNRESECTABLE METASTATIC COLORECTAL CANCER PATIENTS
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000935-42 Sponsor Protocol Number: IJB-GASTON-002-ARTEMIS-Eso Start Date*: 2017-04-20
    Sponsor Name:Institut Jules Bordet
    Full Title: Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction can...
    Medical condition: Adenocarcinomas of the esophagus or gastro-esophageal junction and squamous cell carcinoma of the esophagus.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005136-34 Sponsor Protocol Number: THIO101 Start Date*: 2022-11-16
    Sponsor Name:MAIA Biotechnology, Inc.
    Full Title: A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016091-80 Sponsor Protocol Number: TCD11418 Start Date*: 2010-01-11
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Multicenter, randomized, open label study evaluating a poly(ADP-ribose) polymerase-1(PARP-1) inhibitor, SAR240550 (BSI-201), administered twice weekly or weekly, in combination with gemcitabine/car...
    Medical condition: Metastatic Triple Negative Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 02:06:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA